Yuyu Pharma - Asset Resilience Ratio
Yuyu Pharma (000220) has an Asset Resilience Ratio of 1.74% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Yuyu Pharma strategic asset allocation index to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2011–2024)
This chart shows how Yuyu Pharma's Asset Resilience Ratio has changed over time. See 000220 net asset quality score to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Yuyu Pharma's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 000220 market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩3.65 Billion | 1.74% |
| Total Liquid Assets | ₩3.65 Billion | 1.74% |
Asset Resilience Insights
- Limited Liquidity: Yuyu Pharma maintains only 1.74% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Yuyu Pharma Industry Peers by Asset Resilience Ratio
Compare Yuyu Pharma's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
SIMCERE PHARMAC. GRP LTD
F:S2P |
Drug Manufacturers - Specialty & Generic | 0.44% |
|
Curaleaf Holdings Inc.
TO:CURA |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755 |
Drug Manufacturers - Specialty & Generic | 24.59% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
Annual Asset Resilience Ratio for Yuyu Pharma (2011–2024)
The table below shows the annual Asset Resilience Ratio data for Yuyu Pharma.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.39% | ₩817.27 Million ≈ $553.85K |
₩207.69 Billion ≈ $140.75 Million |
-0.49pp |
| 2023-12-31 | 0.88% | ₩1.75 Billion ≈ $1.19 Million |
₩198.21 Billion ≈ $134.33 Million |
-1.65pp |
| 2022-12-31 | 2.53% | ₩4.94 Billion ≈ $3.35 Million |
₩195.21 Billion ≈ $132.29 Million |
+2.41pp |
| 2020-12-31 | 0.12% | ₩180.00 Million ≈ $121.98K |
₩154.90 Billion ≈ $104.97 Million |
-0.29pp |
| 2018-12-31 | 0.40% | ₩545.95 Million ≈ $369.98K |
₩135.23 Billion ≈ $91.64 Million |
-0.01pp |
| 2017-12-31 | 0.41% | ₩500.00 Million ≈ $338.84K |
₩121.49 Billion ≈ $82.33 Million |
-0.05pp |
| 2016-12-31 | 0.46% | ₩509.59 Million ≈ $345.34K |
₩111.30 Billion ≈ $75.43 Million |
-0.02pp |
| 2015-12-31 | 0.48% | ₩500.00 Million ≈ $338.84K |
₩104.33 Billion ≈ $70.70 Million |
-0.06pp |
| 2014-12-31 | 0.54% | ₩550.00 Million ≈ $372.73K |
₩101.40 Billion ≈ $68.72 Million |
-3.83pp |
| 2013-12-31 | 4.37% | ₩4.21 Billion ≈ $2.85 Million |
₩96.26 Billion ≈ $65.24 Million |
+4.30pp |
| 2012-12-31 | 0.07% | ₩64.39 Million ≈ $43.64K |
₩88.68 Billion ≈ $60.10 Million |
+0.07pp |
| 2011-12-31 | 0.01% | ₩6.49 Million ≈ $4.40K |
₩88.51 Billion ≈ $59.98 Million |
-- |
About Yuyu Pharma
Yuyu Pharma, Inc. develops and markets pharmaceutical products in Korea and United States. The company offers various prescription drugs, non-prescription drugs, quasi-drugs, health functional foods, and other products in the fields of neurology, endocrinology, otolaryngology, etc. The company was formerly known as YuYu Inc. and changed its name to Yuyu Pharma, Inc. in May 2008. Yuyu Pharma, Inc.… Read more